Why we Should Opt Out of the Government's New Patient Database
By Edward Hockings,
The Guardian
| 01. 31. 2014
We have until March to opt out of the
care.data initiative. The ‘
theoretical risk’ that we might be re-identified from our personal data once it is made available to third parties is a compelling reason to opt-out. However, this is not the only reason. Care.data is part of a major legislative programme that includes the Clinical Research Practice Datalink (
CRPD) and the
100,000 genome project – through which whole-sequenced genomes will be put to commercial use. These major infrastructural developments have been accompanied by radical changes to privacy law that have resulted in a cultural shift in the governance of information.
These sweeping changes in privacy law were introduced without consultation, and the risks they entail will be borne by those whose medical records may be accessed without their consent. How did we get to this point? Fourteen years ago, written evidence by SmithKline Beecham to the Select Committee on Health, House of Commons, advanced the view that the “
NHS represents a singular but under-utilised resource for population genetics, and healthcare informatics more generally.”...
Related Articles
By Darren Incorvaia, Fierce Biotech | 07.16.2026
Jennifer Doudna, Ph.D., the Nobel Laureate best known for co-inventing the CRISPR system that has become the foundation for gene editing, is dipping her toes into a new, buzzy field: AI-powered protein design.
In a new paper, published today...
By Risa Cromer, The Conversation | 07.17.2026
By Emily Packard Dawson and Lainie Friedman Ross , The Hastings Center for Bioethics | 07.16.2026
Major news outlets recently reported – based on a bioRxiv preprint – that scientists had edited genes in human embryos with “startling precision.” The scientists’ decision to release this work ahead of peer review, coupled with the extensive media coverage...
Media coverage of recent developments in embryo gene editing might seem to suggest that gene-edited babies are close to becoming a reality. As tech billionaires eager to profit off of techno-eugenics invest in “designer baby” technologies, attempts to normalize heritable genome editing – which remains unsafe and raises significant ethical and societal concerns – are especially dangerous. It’s worth taking a closer look at these developments and what they mean, in a way that pushes back on narratives normalizing the...